fb-pixel tracker

Caris Life Sciences to Present New Research at ASCO 2019

Findings in molecular science will advance and reinvent cancer care for patients

IRVING, Texas, May 21, 2019 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today that it will present new findings to advance and reinvent cancer care at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will be held from May 31 to June 4, 2019, at the McCormick Convention Center in Chicago.

Caris scientists and collaborators from the Caris-led Precision Oncology Alliance™ will present 13 presentations detailing research and associated findings for cancers, including metastatic non-small cell lung cancer, pancreatic cancer and breast cancer, as well as how Caris Next Generation Profiling™, a machine-learning approach to tumor classification, can be used to predict tumor type, particularly in cases of carcinoma of unknown primary (CUP).

“At Caris, we bring together the brightest minds to advance cancer care, and we’re excited to showcase such a wide array of innovative research at ASCO,” said Michael Korn, M.D., Chief Medical Officer at Caris Life Sciences. “Our findings will help oncologists improve clinical outcomes by providing their patients more personalized and, ultimately, more effective treatment that is tailored to specific cancer subtypes.”

In addition to its presentations, Caris will exhibit at booth #4029 from 9 a.m.-5 p.m. Central time on June 1-3. Company executives also will be available for one-on-one meetings during the event.

Caris’ ASCO 2019 presentation schedule:

Saturday, June 1, 8-11 a.m. Central time, Hall A of the McCormick Convention Center:

Tumor mutational burden (TMB) profile of K-RAS/TP-53 co-mutation in metastatic non-small cell lung cancer (m-NSCLC) presented by Abdul Rafeh Naqash, M.D., East Carolina University/Vidant Cancer Center
Abstract Number: 2626
Collaborating Institutions: East Carolina University/ Vidant Cancer Center, Georgetown Lombardi Comprehensive Cancer Center, Karmanos Cancer Institute/Wayne State University, Fox Chase Cancer Center, USC Norris Comprehensive Cancer Center, West Cancer Center & Research Institute, West Virginia University Cancer Institute, Augusta University, Virginia Cancer Specialists

Impact of prior chemotherapy or radiation therapy on tumor mutation burden in NSCLC presented by Sushma Jonna, M.D., Georgetown Lombardi Comprehensive Cancer Center
Abstract Number: 2627
Collaborating Institutions: Georgetown Lombardi Comprehensive Cancer Center, The University of Tennessee Health Science Center, West Cancer Center & Research Institute, USC Norris Comprehensive Cancer Center, The University of Tennessee Health Science Center’s Hematology/Oncology Student Interest Group, LAC+USC Medical Center

Machine learning algorithm analysis using a commercial 592-gene NGS panel to accurately predict tumor lineage for carcinoma of unknown primary (CUP) presented by Jim Abraham, Caris Life Sciences
Abstract Number: 3083
Collaborating Institution: The University of Texas MD Anderson Cancer Center

Molecular differences between lymph nodes (LNs) and distant metastases (mets) in colorectal cancer (CRC) presented by Alberto Puccini, M.D., Keck School of Medicine of USC
Abstract Number: 3130
Collaborating Institutions: Keck School of Medicine of USC, West Virginia University Cancer Institute, West Cancer Center & Research Institute, Karmanos Cancer Institute/Wayne State University, Georgetown Lombardi Comprehensive Cancer Center, USC Norris Comprehensive Cancer Center, Fox Chase Cancer Center, The University of Tennessee Health Science Center, USA Mitchell Cancer Institute, University of California, San Francisco, USC Norris Comprehensive Cancer Center

Actionable coalterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway presented by Arielle Lutterman Heeke, M.D., Levine Cancer Institute
Abstract Number: 3132
Collaborating Institutions: Levine Cancer Institute, Georgetown Lombardi Comprehensive Cancer Center, West Cancer Center & Research Institute, The University of Tennessee Health Science Center

MET exon 14 skipping analogs: rare but potentially clinically actionable presented by Rebecca Feldman, Ph.D., Caris Life Sciences
Abstract Number: 3141

Sunday, June 2, 8-11 a.m. Central time, Hall A of the McCormick Convention Center:

DNA damage response and repair (DDR) gene mutations and correlation with tumor mutation burden (TMB) in non-small cell lung cancer (NSCLC) presented by Hirva Mamdani, M.D., Karmanos Cancer Institute
Abstract Number: 9100
Collaborating Institutions: Karmanos Cancer Institute/Wayne State University, USC Norris Comprehensive Cancer Center, East Carolina University/Vidant Cancer Center, Georgetown Lombardi Comprehensive Cancer Center, West Virginia University Cancer Institute, West Cancer Center & Research Institute, Fox Chase Cancer Center, Augusta University, The University of Tennessee Health Science Center, Virginia Cancer Specialists, Indiana University School of Medicine

Monday, June 3, 8-11 a.m. Central time, Hall A of the McCormick Convention Center:

Molecular landscape of colorectal cancers harboring R-spondin fusions presented by Andreas Seeber, M.D., Ph.D., Innsbruck Medical University
Abstract Number: 3588
Collaborating Institutions: Tyrolean Cancer Research Institute, Keck School of Medicine of USC, West Virginia University Cancer Institute, West Cancer Center & Research Institute, The University of Tennessee Health Science Center, Karmanos Cancer Institute/Wayne State University, Georgetown Lombardi Comprehensive Cancer Center, USC Norris Comprehensive Cancer Center, Fox Chase Cancer Center

Gene mutations of SWI/SNF complex and molecular profile in colorectal cancer presented by Ryuma Tokunaga, M.D., Ph.D., USC Norris Comprehensive Cancer Center
Abstract Number: 3600
Collaborating Institutions: USC Norris Comprehensive Cancer Center, Keck School of Medicine of USC, West Virginia University Cancer Institute, Karmanos Cancer Institute/Wayne State University, Innsbruck Medical University, Chiba Cancer Center, Levine Cancer Institute, Georgetown Lombardi Comprehensive Cancer Center

Molecular comparison between peritoneal metastases (PM) and primary gastric (GC) and gastroesophageal junction (GEJ) cancer presented by Matthew K. Stein, M.D., West Cancer Center & Research Institute
Abstract Number:
4053
Collaborating Institutions: The University of Tennessee Health Science Center, West Virginia University Cancer Institute, Karmanos Cancer Institute/Wayne State University, Levine Cancer Institute, USC Norris Comprehensive Cancer Center

Frequency of BRCA mutation in biliary tract cancer and its correlation with tumor mutational burden (TMB) and microsatellite instability (MSI) presented by Gilbert Spizzo, M.D., Innsbruck Medical University, Tyrolean Cancer Research Institute
Abstract Number: 4085
Collaborating Institutions: Keck School of Medicine of USC, West Virginia University Cancer Institute, West Cancer Center & Research Institute, Karmanos Cancer Institute/Wayne State University, The University of Tennessee Health Science Center, USA Mitchell Cancer Institute, Georgetown Lombardi Comprehensive Cancer Center, USC Norris Comprehensive Cancer Center, Fox Chase Cancer Center, University of California, San Francisco

Association of BRCA-mutant pancreatic cancer with high tumor mutational burden (TMB) and higher PD-L1 expression presented by Andreas Seeber, M.D., Ph.D., Innsbruck Medical University, Tyrolean Cancer Research Institute
Abstract Number: 4133
Collaborating Institutions: Keck School of Medicine of USC, West Virginia University Cancer Institute, West Cancer Center & Research Institute, The University of Tennessee Health Science Center, Karmanos Cancer Institute/Wayne State University, Georgetown Lombardi Comprehensive Cancer Center, USC Norris Comprehensive Cancer Center, Fox Chase Cancer Center

Monday, June 3, 1:15-4:15 p.m. Central time, Hall A of the McCormick Convention Center:

Molecular profiling of melanoma brain metastases (MBM) compared to primary cutaneous melanoma (CM) presented by Gino Kim In, M.D., M.P.H., USC Norris Comprehensive Cancer Center
Abstract Number: 9565
Collaborating Institutions: John Wayne Cancer Institute, Fox Chase Cancer Center, Virginia G. Piper Cancer Center at HonorHealth, Hoag Family Cancer Institute, Karmanos Cancer Institute/Wayne State University, Moffitt Cancer Center, Georgetown Lombardi Comprehensive Cancer Center, The University of Tennessee Health Science Center, West Cancer Center & Research Institute

 

 

About Caris Life Sciences
Caris Life Sciences® is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. The company’s suite of market-leading molecular profiling offerings assess DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions. Caris is also advancing precision medicine with Next Generation Profiling™ that combines its innovative service offerings, Caris Molecular Intelligence® and ADAPT Biotargeting System™, with its proprietary artificial intelligence analytics engine, DEAN™, to analyze the whole exome, whole transcriptome and complete cancer proteome. This information, coupled with mature clinical outcomes on thousands of patients, provides unmatched molecular solutions for patients, physicians, payers and biopharmaceutical organizations. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Asia and other international markets. To learn more, please visit www.CarisLifeSciences.com or follow us on Twitter (@CarisLS).

 

# # #

Company Contact:
Srikant Ramaswami
Vice President, Chief Communications Officer
sramaswami@carisls.com
+1-214-769-5510

Investor Inquiries:
David Clair, CFA
Westwicke Partners
david.clair@icrinc.com
+1-646-277-1266

The post Caris Life Sciences to Present New Research at ASCO 2019 appeared first on Caris Life Sciences.